

LS 2 PM-H-200

2729-822 2

The Pharmacology of Alcohol Abuse

Contributors

R.F. Anton, H.C. Becker, B.J. Berg, M.J. Bohn, K.E. Bremner
D.A. Ciraulo, R.K. Fuller, J. Gelernter, K.A. Grant, D. Hersh
G.A. Higgins, P.L. Hoffman, C.M. Knapp, H.R. Kranzler
A. Dzung Lê, S.W. Leslie, R.Z. Litten, J. Littleton, P. Manu
A.T. McLellan, A.K. Mehta, J. Moring, C. Müller, C.A. Naranjo
M.K. Romach, H. Rommelspacher, H.H. Samson, B.F. Sands
E.M. Sellers, W.J. Shoemaker, M.K. Ticku, D.M. Tomkins
J.R. Volpicelli, N.T. Watson, T.M. Worner

Editor

Henry R. Kranzler



Springer-Verlag
Berlin Heidelberg New York London Paris
Tokyo Hong Kong Barcelona Budapest

Contents

CHAPTER 1

The Pharmacology of Alcohol Abuse: An Introduction

H.R. KRANZLER.....	1
References.....	10

CHAPTER 2

Alcohol-Induced Changes in Neuronal Membranes

J. MORING and W.J. SHOEMAKER. With 1 Figure	11
A. Introduction	11
B. Historical Overview	11
I. The Meyer-Overton Hypothesis	11
II. Membrane Disorder	14
C. Membrane Lipid Effects	15
I. Disordering of Membranes by Acute Ethanol	15
II. Partitioning of Ethanol into Membranes	17
III. Pressure Reversal of Acute Effects of Ethanol	19
IV. Membrane Lipid Composition Changes	
Due to Chronic Ethanol Exposure	20
1. Phospholipids	20
2. Cholesterol	21
3. Acyl Chain Composition	22
4. Do Lipid Composition Changes Cause Tolerance	
or Change Membrane Function?	23
V. Effects of Ethanol on Membrane Lipid Domains	24
1. Lipid Classes	24
2. Transbilayer Lipid Distribution	25
3. Annular Lipids	26
4. Lateral Membrane Domains	27
VI. Ethanol-Induced Hypothermia	27
VII. Lipid Effects on Proteins	28
D. Membrane Protein Effects	29
I. Direct Effects of Acute Ethanol on Proteins	29

1. Firefly Luciferase	29
2. The GABA _A Receptor	30
II. Protein Model of the Anesthetic Cutoff Effect	31
III. Effects of Ethanol on Calcium Channels	32
IV. Effects of Ethanol on Intracellular Calcium	34
V. Effects of Ethanol on G-Protein-Related Systems	35
1. Acute Effects on Protein Kinase C	36
2. The Adenylyl Cyclase System	37
3. Chronic Effects	37
VI. Effects of Chronic Ethanol on Receptor Subunit Expression	39
1. The GABA _A Receptor	40
2. Origin of mRNA Effects	41
E. Conclusions	41
References	43

CHAPTER 3

Effects of Ethanol on Voltage-Dependent Calcium Channel Function

S.W. LESLIE	55
A. Voltage-Dependent Calcium Channels	55
I. Introduction	55
II. L Type Channels	55
III. N, P, and T Type Channels	58
1. Conclusions	60
B. Effects of Ethanol and Other Sedative-Hypnotic Drugs on Voltage-Dependent Calcium Channels	60
I. Ethanol Effects on Ion Channels	60
II. Ethanol Effects on Different Types of Calcium Channel	62
III. Brain Regional Differences in the Effects of Ethanol	64
IV. Chronic Ethanol Effects on Calcium Channels	65
V. Calcium Channel Blockers and Ethanol Preference	66
VI. Conclusions	67
C. Effects of Barbiturates and Benzodiazepines on Calcium Channels	67
I. Conclusions	69
References	69

CHAPTER 4

Effects of Alcohol on Excitatory Amino Acid Receptor Function

P.L. HOFFMAN	75
A. Introduction	75
I. Site of Action of Ethanol: Protein Versus Lipid	75

B. Ethanol and Excitatory Amino Acid Receptors	76
I. Characteristics of Glutamate Receptors	76
II. Ethanol and NMDA Receptor Function: Acute Effects .	79
1. Mechanism of Action of Ethanol	81
2. Effects of Anesthetics and Sedative Hypnotics.....	81
3. Ethanol and the NMDA Receptor In Vivo.....	83
4. Ethanol and the NMDA Receptor in Development	85
III. Ethanol and NMDA Receptor Function: Chronic Effects	86
1. Role of NMDA Receptors in Ethanol Withdrawal (Physical Dependence)	88
2. Role of NMDA Receptors in Ethanol Tolerance....	91
3. Role of NMDA Receptors in Opiate Tolerance and Dependence	94
C. Summary: Ethanol and the NMDA Receptor.....	95
References.....	96

CHAPTER 5

Effects of Alcohol on GABA-Mediated Neurotransmission	
M.K. TICKU and A.K. MEHTA	103
A. Introduction	103
B. Behavioral Studies	104
C. Binding Studies	105
D. Functional Studies	106
I. Electrophysiological Studies	106
II. Chloride Flux	107
E. Ro15-4513: Ethanol Antagonist	108
F. Molecular Biological Studies	110
G. Chronic Ethanol Treatment and GABA Receptor Gene Expression	112
H. Conclusions	112
References.....	113

CHAPTER 6

Involvement of CNS Catecholamines in Alcohol Self-Administration, Tolerance, and Dependence: Preclinical Studies	
H.A. SAMSON and P.L. HOFFMAN	121
A. Introduction	121
B. Acute Effects of Investigator-Administered Ethanol: Potential for Catecholamine Involvement in Ethanol Reinforcement	121

I. Norepinephrine	121
II. Dopamine	123
C. Oral Ethanol Self-Administration in Nonoperant Situations	124
I. Limited Access Ethanol Drinking Situations	124
1. Norepinephrine	124
2. Dopamine	124
II. Continuous Access Ethanol Drinking Situations	125
1. Norepinephrine	125
2. Dopamine	125
III. Operant Paradigms of Oral Ethanol Self-Administration	126
1. Norepinephrine	126
2. Dopamine	126
D. Chronic Effects of Ethanol on Noradrenergic and Dopaminergic Activity	127
I. Norepinephrine	127
II. Dopamine	129
E. Role of Catecholamines in Ethanol Tolerance and Physical Dependence	130
I. Tolerance	130
II. Physical Dependence	131
F. Summary	132
References	133

CHAPTER 7

5-HT Mediation of Alcohol Self-Administration, Tolerance, and Dependence: Pre-Clinical Studies

G.A. HIGGINS, A.D. LÊ, and E.M. SELLERS. With 3 Figures	139
A. Introduction	139
B. Overview of the 5-HT System: Morphology and Receptors	139
C. 5-HT and Alcohol Self-Administration	141
I. Increasing 5-HT Function	141
1. Indirect 5-HT Agonists and Alcohol Self-Administration	141
2. 5-HT Receptor Agonists and Alcohol Self-Administration	143
3. Treatments that Enhance 5-HT Function and Other Consummatory Behaviours	145
4. Treatments that Enhance 5-HT Function and Other Drug-Reinforced Behaviour	147
II. Reducing 5-HT Function	147
1. 5-HT Receptor Antagonists and Alcohol Self-Administration	147
2. 5-HT Lesions and Alcohol Self-Administration	149

3. Treatments that Reduce 5-HT Function and Other Consummatory Behaviours	150
4. Treatments that Reduce 5-HT Function and Other Drug-Reinforced Behaviour	150
III. Biochemical Factors	151
IV. Summary	152
D. 5-HT, Alcohol Tolerance, and Physical Dependence	155
I. General Aspects of Alcohol Tolerance	155
1. Definition and Classification	155
2. Features of Ethanol Tolerance	156
II. Role of 5-HT in Ethanol Tolerance/Dependence	156
III. Differences in 5-HT Regulation of Ethanol Drinking and Ethanol Tolerance	157
IV. 5-HT and Ethanol Dependence	158
E. Effects of Chronic Ethanol Administration on 5-HT Receptors	158
I. Intoxication	158
F. Interaction of 5-HT and Opioids	159
G. General Summary	159
References	160

CHAPTER 8

Opioid Mediation of Alcohol Self-Administration: Pre-Clinical Studies

J.R. VOLPICELLI, B.J. BERG, and N.T. WATSON	169
A. Introduction	169
B. Alcohol Drinking Enhances Opioid System Activity	169
I. Opioid Peptides Are Produced in the Metabolism of Alcohol (TIQ Alkaloid Hypothesis)	169
II. Alcohol Drinking Leads to Changes in Opioid Receptor Sensitivity	170
III. Alcohol Drinking Leads to the Release of Endogenous Opioids	171
C. Genetic Susceptibility to Alcohol Abuse	171
D. Modulating Opiate Receptor Activity Influences Alcohol Drinking	172
I. Low Doses of Opioids Increase Alcohol Drinking	173
II. Moderate to High Doses of Opioids Suppress Alcohol Drinking	174
III. Alcohol Drinking Increases During Opiate Withdrawal	175
E. Uncontrollable Stress and Alcohol Abuse	175
I. Post-Stress Alcohol Drinking	176
F. Opiate Antagonists Attenuate Alcohol Drinking	176
I. Why Do Organisms Abuse Alcohol?	178
G. Summary	180
References	181

CHAPTER 9

Animal Models of the Alcohol Addiction Process

K.A. GRANT	185
A. Introduction	185
B. Alcohol-Seeking Behavior	186
C. Initiation	188
I. Models to Assess Environmental Effects in the Initiation of Alcohol-Seeking	189
II. Models to Assess the Genetic Basis of Initiation of Alcohol-Seeking	192
III. Models to Assess the Psychopharmacological Basis of Initiation of Alcohol-Seeking	195
D. Transition to Abuse and Dependence (Maintenance)	201
I. Role of Tolerance in the Maintenance of Excessive Alcohol-Seeking	202
II. Role of Sensitization in the Maintenance of Excessive Alcohol-Seeking	204
III. Role of Dependence in the Maintenance of Excessive Alcohol-Seeking	206
IV. Role of Environmental Interactions in the Maintenance of Excessive Alcohol-Seeking Behavior	208
V. Role of Conditioned Effects in the Maintenance of Excessive Alcohol-Seeking Behavior	211
E. Remission/Treatment	212
I. Nonpharmacological Treatments to Reduce Alcohol Consumption	213
II. Pharmacological Treatments to Reduce Alcohol Consumption	213
F. Relapse	215
I. Role of Conditioned Withdrawal in the Relapse Process	215
II. Role of Conditioned Drug-Like Effects in the Relapse Process	216
G. Summary	218
References	218

CHAPTER 10

Ethanol and Neurohormonal Regulation

J. LITTLETON	231
A. Effects of Ethanol on Neurohormones	231
I. Hypothalamic-Pituitary-Gonadal Axis	233
1. Gonadotropin-Releasing Hormone Secretion	234

2. Gonadotropin Secretion	234
3. Gonadal Endocrine Secretion	235
4. Gonadal Steroid Metabolism	236
5. Consequences of Alterations in the HPG Axis	237
6. Hypothalamic-Pituitary-Gonadal Axis and Fetal Development	237
7. Conclusions	239
II. Hypothalamic-Pituitary-Adrenal Axis	239
1. Corticotropin-Releasing Hormone Secretion	240
2. Adrenocorticotrophic Hormone Secretion	240
3. Adrenal Steroids	241
4. Consequences of Alterations in the HPA Axis	242
5. Hypothalamic-Pituitary-Adrenal Axis and Fetal Development	243
6. Conclusions	244
III. Hypothalamic-Pituitary-Thyroid Axis	244
1. Thyrotropin-Releasing Hormone and TSH Secretion	244
2. Thyroid Hormones	245
3. Consequences of Alterations in the HPT Axis	246
4. Conclusions	246
IV. Other Neurohormonal Systems	246
1. Growth Hormone	247
B. Role of Neurohormonal Alterations in Ethanol Consumption	248
I. Opioid Peptides	249
II. Hypothalamic-Pituitary-Adrenal Axis	250
III. Appetitive Systems	252
C. Overall Conclusions	253
References	254

CHAPTER 11

Clinical Application of Findings from Animal Research on Alcohol Self-Administration and Dependence

M.K. ROMACH and D.M. TOMKINS	261
A. Overview	261
B. Alcohol Consumption	261
I. Clinical Aspects of Alcoholism	261
II. Animal Models of Alcoholism	265
1. Self-Administration	266
2. Drug Discrimination	267
3. Genetic Strains	268
III. Preclinical Studies	268
1. Serotonin	268

- 2. Opioids 270
- 3. Dopamine 271
- IV. Clinical Studies 272
 - 1. Serotonin 272
 - 2. Opioids 275
 - 3. Dopamine 277
- C. Alcohol Withdrawal 277
 - I. Preclinical Studies 277
 - II. Clinical Studies 279
- D. Comorbidity 281
 - I. Overview 281
 - II. Animal Models 282
 - III. Clinical Studies 283
 - 1. Depression 283
 - 2. Anxiety 284
- E. Conclusions 285
- References 287

CHAPTER 12

Genetic Factors in Alcoholism: Evidence and Implications

- J. GELERNTER 297
 - A. Introduction 297
 - B. Clinical Studies: Familial Patterns in Alcohol Use 298
 - I. Adoption Studies 298
 - II. Twin Studies 301
 - III. Other Clinical Data Bearing on Genetics 303
 - IV. Trait Markers and Differences Between Familial and Nonfamilial Alcoholism 303
 - C. Laboratory Studies: Search for a Molecular Basis for a Complex Behavior 303
 - I. Linkage Studies 304
 - II. Association Studies 304
 - 1. Alcohol-Metabolizing Enzymes 305
 - 2. D₂ Dopamine Receptor Gene 306
 - D. Conclusions 308
 - References 309

CHAPTER 13

Pharmacotherapy and Pathophysiology of Alcohol Withdrawal

- R.F. ANTON and H.C. BECKER. With 3 Figures 315
 - A. Introduction 315

B. Clinical Syndrome	316
I. Phenomenology and Description	316
II. Drinking Variables Related to the Alcohol Withdrawal Syndrome	318
III. Protracted Alcohol Withdrawal	319
IV. Psychiatric Comorbidity and Alcohol Withdrawal	320
C. Pathophysiology of Alcohol Dependence and Withdrawal	322
I. GABA-A Receptor System	322
II. NMDA Receptor System	325
III. Voltage-Operated Calcium Channels	326
IV. Monoamine Systems	328
V. Second Messenger Systems and Adenosine	330
VI. Summary	331
D. Repeated Episodes of Alcohol Withdrawal: The "Kindling" Hypothesis	332
E. Treatment of Alcohol Withdrawal	337
F. Measurement of the Alcohol Withdrawal Syndrome	337
G. Nonpharmacologic Treatment of Alcohol Withdrawal	338
H. Pharmacologic Treatment	339
I. Complicated Alcohol Withdrawal	339
II. Uncomplicated Alcohol Withdrawal	341
III. Benzodiazapines	341
IV. Alpha- and Beta-Adrenergic Blockers	347
V. Anticonvulsants	348
VI. Miscellaneous Treatments	349
I. Treatment of Alcohol Withdrawal Seizures	350
J. Biologic Aspects of Alcohol Withdrawal in Man	352
References	354

CHAPTER 14

Drugs to Decrease Alcohol Consumption in Humans: Aversive Agents

R.K. FULLER and R.Z. LITTEN	369
A. Introduction	369
B. Absorption, Metabolism, and Excretion	370
C. Pharmacokinetics	370
D. Mechanism of Disulfiram: Ethanol Reaction	371
E. Clinical Use	371
F. Efficacy	372
G. Enhancing Disulfiram Compliance	374
H. Toxicity	377
I. Contraindications to Disulfiram Treatment	378
J. Calcium Carbamide	378
K. Future Research Directions	379
References	379

CHAPTER 15

Drugs Attenuating Alcohol Consumption in Humans Through Effects on Various Neurotransmitter Systems

C. A. NARANJO and K. E. BREMNER	383
A. Introduction	383
B. Serotonin	383
C. Dopamine	388
D. Opioids	388
E. Medications Acting on Other Neurotransmitter Systems	389
F. Conclusions	390
References.....	391

CHAPTER 16

Pharmacology of Gastrointestinal Comorbidity in Alcoholics

T.M. WORNER and P. MANU	395
A. Introduction	395
B. Drug Therapy for Alcohol-Induced Liver Disease	396
I. Steatosis	396
II. Alcoholic Hepatitis	396
1. Insulin and Glucagon	397
2. Corticosteroids	397
3. Anabolic Steroids	398
4. Colchicine	398
5. Propylthiouracil	398
III. Cirrhosis	399
1. Ascites	400
2. Encephalopathy	400
3. Esophageal Varices	402
IV. Liver Transplantation	403
C. Drug Therapy of Acute Alcoholic Pancreatitis	403
1. Cimetidine	403
2. Somatostatin	404
3. Pirenzepine	405
D. Drug Therapy of Chronic Alcoholic Gastritis	406
E. Summary	407
References.....	407

CHAPTER 17

Drugs for the Treatment of Psychiatric Comorbidity in Alcoholics: Recent Developments

M.J. BOHN and D. HERSH	415
------------------------------	-----

A. Introduction	415
B. Depression	416
I. Assessment	419
II. Treatment	419
III. Pharmacotherapy	420
1. Cyclic Antidepressants	421
2. Monoamine Oxidase Inhibitors	423
3. Serotonin Uptake Inhibitors	424
4. Lithium	424
C. Anxiety Disorders	425
I. Assessment	427
II. Treatment	427
III. Pharmacotherapy	427
D. Bipolar Affective Disorder	429
I. Assessment	430
II. Treatment	431
III. Pharmacotherapy	431
E. Schizophrenia	433
I. Assessment	434
II. Treatment	435
III. Pharmacologic Treatment	435
F. Conclusions	436
References	437

CHAPTER 18

Clinical Markers of Alcohol Abuse

H. ROMMELSPACHER and C. MÜLLER	443
A. Introduction	443
I. Definition of the Term "Marker"	443
B. Ethanol, Acetaldehyde, and Acetate	445
I. Ethanol	445
II. Acetaldehyde	446
III. Acetaldehyde-Hemoglobin Adduct	446
IV. Acetate	448
C. Monoamine Oxidase	448
I. Regulation of Enzyme Activity	448
II. In Vitro Effects of Ethanol	449
III. Enzyme Activity in Alcoholics and Nonalcoholics	449
IV. In Vitro Studies of Platelets from Alcoholics	451
D. Guanine Nucleotide Binding Proteins and Adenylyl cyclase	451
I. Acute Effects of Ethanol	452
II. Chronic Effects of Ethanol	452
E. Serum Enzymes	453
I. γ -Glutamyltransferase	454

II. Aspartate Aminotransferase	454
III. Other Enzymes, Indices, and Test Combinations	455
F. Tetrahydroisoquinolines and β -Carbolines	455
I. Tetrahydroisoquinolines	456
II. β -Carbolines	457
G. Immune System	458
I. Blood Groups	458
II. Immunoglobulins	458
III. Human Leukocyte Antigens	458
IV. Cell-Mediated Immune Function	459
H. Alcohol Intake and Serum Trace Elements	459
I. Trace Elements and Electrolytes	459
II. Thiamine (Vitamin B ₁)	459
I. Carbohydrate-Deficient Transferrin	460
I. Biochemistry	460
II. Methodological Approaches	461
III. Performance: Sensitivity and Specificity	462
J. Conclusion	463
References	464

CHAPTER 19

Interaction of Alcohol with Therapeutic Drugs and Drugs of Abuse

B.F. SANDS, C.M. KNAPP, and D.A. CIRAULO	475
A. Introduction	475
B. Pharmacokinetic Mechanisms	476
I. Bioavailability and Absorption	476
II. Distribution	477
III. Metabolism	478
C. Pharmacodynamic Mechanisms	480
D. Individual Drugs	484
I. Acetaminophen	484
II. Angiotensin-Converting Enzyme Inhibitors	484
1. Enalapril	484
III. Anticonvulsants	484
1. Phenytoin	484
IV. Antidepressants	485
1. Amitriptyline	485
2. Imipramine	485
3. Clomipramine	486
4. Desipramine	486
5. Doxepin	486
6. Nortriptyline	486
V. Serotonin Selective Reuptake Inhibitors	487

VI. Antipyrene	487
VII. Ascorbic Acid	487
VIII. Barbiturates	488
1. Phenobarbital	488
2. Pentobarbital	488
IX. Benzodiazepines	488
1. Chlordiazepoxide	488
2. Diazepam	488
3. Flurazepam	490
4. Lorazepam	490
5. Triazolam	490
X. Bromocriptine	491
XI. Ca ²⁺ Blockers	491
1. Nifedipine	491
2. Nimodipine	491
3. Verapamil	491
XII. Cannabis	492
XIII. Cocaine	492
XIV. Sodium Warfarin	494
XV. Cromoglycate	494
XVI. Disulfiram	494
XVII. H ₂ Blockers	495
1. Cimetidine	495
2. Famotidine	495
3. Ranitidine	495
XVIII. Lithium Carbonate	496
XIX. Methylxanthines	496
1. Caffeine	496
2. Theophylline	496
XX. Metoclopramide	497
XXI. Neuroleptics	497
1. Chlorpromazine	497
2. Remoxipride	497
3. Thioridazine	497
XXII. Nitrates	498
1. Nitroglycerin	498
XXIII. Opioids	498
1. Methadone	499
2. Propoxyphene	499
XXIV. Oral Contraceptives	499
XXV. Oral Hypoglycemics	500
1. Chlorpropamide	500
2. Tolbutamide	500
XXVI. Sedative-Hypnotics	500
1. Chloral Hydrate	500

2. Glutethimide	501
3. Meprobamate	501
XXVII. Salicylates	501
XXVIII. Tobacco	501
References	502

CHAPTER 20

Pharmacotherapies for Alcoholism: Theoretical and Methodological Perspectives

H.R. KRANZLER, A.T. MCLELLAN, and M.J. BOHN	513
A. Pharmacologic Approaches to Relapse Prevention in Alcoholics	513
B. Treatment Matching	514
I. Matching Based Upon Comorbid Psychopathology	514
1. Anxiety and Alcoholism	515
2. Depression and Alcoholism	515
II. Matching Based Upon Other Patient Characteristics ...	516
1. Cloninger's Typology	517
2. The "Type A/Type B" Distinction of Babor and Colleagues	518
C. Methodologic Issues in Clinical Trials with Alcoholics	520
I. Patient Assessment and Outcome Measurement: "For Whom Is One Drink Too Many?"	522
II. Treatment Retention and "How Much Additional Treatment Is Too Much Treatment?"	524
1. Preventing Attrition	525
2. Analysis of Outcomes When Attrition Occurs	527
III. Maximizing Compliance and Determining "How Well You've Done"	527
IV. "How Long to Treat? Then What?"	530
D. What May the Future Hold?	531
References	532
Subject Index	539